LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin
Prue A. Cowin(Broad Institute), David D.L. Bowtell(The University of Melbourne), Anna DeFazio(The University of Sydney), Elizabeth Loehrer(Erasmus MC), Michael S. Anglesio(University of British Columbia), Peter J. Campbell(Wellcome Sanger Institute), Elizabeth L. Christie(Peter MacCallum Cancer Centre), Karen E. Sheppard(The University of Melbourne), Sarah Ftouni(Peter MacCallum Cancer Centre), Joshy George(Jackson Laboratory), Michael Quinn(University of Rochester), Joy Hendley(Peter MacCallum Cancer Centre), Viola Heinzelmann‐Schwarz(Roche (Switzerland)), Sián Fereday(Peter MacCallum Cancer Centre), Laura Galletta(Peter MacCallum Cancer Centre), Carleen Cullinane(Peter MacCallum Cancer Centre), Paul R. Harnett(The University of Sydney), Peter Van Loo(Wellcome Sanger Institute), Dariush Etemadmoghadam(Peter MacCallum Cancer Centre), Leanne Bowes(Peter MacCallum Cancer Centre), Richard B. Pearson(The University of Melbourne), Orla McNally(Royal Women's Hospital), Michael Friedländer(Prince of Wales Hospital)
Cited by 113
Related Papers
COSMIC: the Catalogue Of Somatic Mutations In Cancer
|Nucleic Acids Research|2018|5.2k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
The cancer genome
|Nature|2009|3.5k
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k